# Why are Top Scientists Suddenly Adopting Our 30-Year-Old Strategy? | Eliaz Therapeutics

- Canonical URL: https://wefunder.com/feed/183434
- Entity ID: wefunder:feed_item:183434
- Published at: 2025-07-03 13:57:36 UTC
- Updated at: 2025-07-17 18:15:12 UTC

## Author
Dr. Isaac Eliaz (MD)

## Subject
Eliaz Therapeutics

## Content
Dear friends,For decades, a truly effective treatment for sepsis was out of reach. As a physician, I’ve seen firsthand how broad, non-specific therapies often failed to stop the runaway inflammation that makes sepsis so deadly. It gives me great hope to finally see a fundamental shift is happening in sepsis research, one that places our mission at the forefront of modern medicine. A wave of new scientific research confirms the future of sepsis care lies in a new direction. The latest findings, such as emerging research into new drug targets like the VHR enzyme (1) and TLR4 antagonists (2)—show a pivot away from broad approaches toward highly-specific, targeted therapies that can impact the core drivers behind sepsis. This is the very principle that guided my life’s work for 30 years, and to see the broader scientific community now turn toward a targeted philosophy is deeply validating on a personal and professional level. But this validation isn’t just mine. It’s yours as well.While the wider scientific community is only now beginning to adopt this approach, you saw the potential from the start. You understood the vision and placed your trust in this strategy long before it became the consensus. For that, I am profoundly grateful. Thank you for your support, foresight, and sharing in this belief. Together, we are on a path to changing sepsis care forever!Yours in health, Isaac Eliaz, MD, MS, LAcCitations: https://www.drugtargetreview.com/news/158104/new-drug-discovery-approach-offers-hope-for-sepsis-treatment/https://synapse.patsnap.com/article/what-are-the-current-trends-in-sepsis-treatment-research-and-development